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CME: Cardiology
Cardiovascular disease (CVD) accounts for approximately 30% of 
deaths worldwide, with 80% of this burden in developing countries. 
The epidemiological transition occurring in sub-Saharan Africa 
(SSA) has the consequence of economic and social transformation, 
resulting in dramatic shifts in disease spectrum from communicable 
diseases and malnutrition to CVD and cancer. South Africa (SA) 
is faced with the challenge of four colliding epidemics: (i) poor 
child and maternal health; (ii) high rates of interpersonal violence; 
(iii)  infectious diseases, including HIV/AIDS and tuberculosis; and 
(iv) non-communicable diseases (NCDs), including CVD. In SA, 
NCDs are prevalent in both rural and urban areas, most prominently 
in poor persons living in urban and periurban settings, resulting 
in increasing pressure on acute and chronic healthcare services. 
A major driver of this NCD burden is the demographic change 
in the country, leading to an increase in the proportion of people 
aged over 60 years despite the negative effect of HIV/AIDS on 
life expectancy. Contributions to the CVD burden in the country 
include hypertension, cardiomyopathies, rheumatic valvular heart 
disease, pericardial disease and coronary artery disease, among 
others. In this issue of SAMJ, the clinical approaches to these 
common cardiovascular problems are reviewed with the dual aim of 
empowering the doctors who manage these conditions in primary 
care settings around the country as well as improving the care of 
CVD in primary care settings and in emergency departments. This 
outstanding series of articles represents the collaborative effort of 
primary health/family physicians and cardiologists from around 
the country. The authors have synthesised and presented the most 
current, evidence-based and practical approaches to management of 
common CVDs. The series will be split over January and February, as 
the CME articles are now printed in full.
Kangaroo mother care
Our guest editorial[1] informs of the National Department of Health’s 
use of mobile technology – mHealth – to improve maternal, child and 
youth health and treatment of HIV patients. 
More than 20 million infants are born weighing less than 2 500 g 
every year – over 96% of them in developing countries – and are 
at increased risk of early growth retardation, infectious disease, 
developmental delay and death during infancy and childhood.[2] 
Kangaroo mother care (KMC)[3] is a safe and effective alternative to 
conventional neonatal care, which is expensive and needs both highly 
skilled personnel and permanent logistic support. 
Feucht et al.[4] report on how the district clinical specialist team, in 
conjunction with experienced local KMC implementers, embarked 
on a quality improvement initiative from 2013 to 2015 to facilitate 
KMC scale-up in the context of the Tshwane district’s increase in 
deliveries, the strain on obstetric and neonatal services at the larger 
secondary and tertiary hospitals, and neonatal bed shortages in SA. 
Taking technology one step further, Chilean ‘techies’ calling 
themselves ‘Team BabyBe’ have designed a bionic mattress for a 
premature infant in an incubator in the neonatal intensive care unit. 
The mattress feels like real human skin, and is teamed with a turtle-
like sensor worn on the parent’s chest to detect his or her heartbeat 
and breathing patterns. Information from the sensor is sent to a 
control module that transmits the information to a pneumatic pump 
in the mattress that makes the mattress move – so that the baby feels 
the parent’s heartbeat and breathing.[4] 
Treating type 2 diabetes mellitus (DM)
Type 2 DM, set to increase by more than 100% over the next decade 
in SSA and with its prevalence in SA’s over-30s having doubled, has 
the potential to be as disruptive as the HIV pandemic in lowering 
life expectancy and reversing previous healthcare gains. Against this 
background, Wing and Jivan[5] present a review entitled ‘Targeting 
composite treatment of type 2 diabetes in middle-income countries – 
walking a tightrope between hyperglycaemia and the dangers of 
hypoglycaemia’. We well recognise diabetic complications. In SA 
these are reckoned to account for 78 900 years lost to disability (YLD), 
8 000 new cases of blindness, 2 000 new amputations, 7 000 strokes 
and 5 500 YLD attributable to ischaemic heart disease. According to 
the WHO Multinational Study of Vascular Disease in Diabetes, half 
of all deaths in type 2 DM are attributable to cardiovascular disease.
While intensive glucose control reduces the overall risk of diabetes-
related sequelae such as diabetic retinopathy, the downside is an 
increased risk of hypoglycaemia and weight gain. Additionally, the 
ACCORD study – among others – as outlined in this review has 
identified the increased mortality linked to intensive glucose control 
in patients with multiple cardiovascular risk factors. Hypoglycaemia 
has the potential to prompt episodes of syncope, ventricular 
tachyarrhythmias and cardiac arrest, induces a procoagulant and 
prothrombotic state, and, counterintuitively, creates a favourable 
environment for the development of atherosclerosis. New incretin-
based therapies, such as the glucagon-like peptide 1 analogues and 
the di-peptidyl peptidose-4 inhibitors, carry an overall lower risk of 
hypoglycaemia than the sulphonylureas and insulin and are favoured 
agents to minimise the extent of hypoglycaemia while still ensuring 
that patients reach appropriate glucose control targets.
Importance of screening for porphyria
In ‘Severe porphyric neuropathy – importance of screening for 
porphyria in Guillain-Barré syndrome’, Schutte et al.[6] remind us 
to consider an acute porphyric attack in patients who present with 
progressive quadriparesis, characterised by weakness and reduced 
reflexes, and in whose history there has been a recent change in 
medication. In two patients in this case series, the attack was probably 
precipitated by antiretroviral medication – one patient was started on 
highly active antiretroviral therapy before the onset of the symptoms, 
and the other took antiretroviral medication for post-exposure 
prophylaxis. The therapy of choice in an acute porphyric attack is 
haemin, which limits or reverses the toxic effects of haem precursors 
on the peripheral nerves. The weakness then resolves rapidly. 
Unfortunately haemin was not readily available in the authors’ public 
sector hospital setting.
Antenatal screening for hepatitis B virus 
(HBV) in HIV-infected and uninfected 
pregnant women in Tshwane[7]
In SA, there is a significantly higher HBV prevalence in HIV-infec ted 
as opposed to HIV-uninfected women. The risk of vertical perinatal 
transmission of HBV to the infant is 10 - 20% in pregnant women 
who are seropositive for hepatitis B surface antigen (HBsAg) but 
seronegative for hepatitis e antigen (HBeAg); however, perinatal 
transmission rises to 90% if a mother is seropositive for both HBsAg 
and HBeAg. Currently pregnant women are not screened for HBV in 
the public sector, placing neonates at risk of acquiring HBV infection 
from exposure to maternal blood and secretions during delivery. In 
the current national vaccination schedule, HBV vaccination is only 
started at 6 weeks. The authors call, as Spearman and Sonderup[8] 
already have in this journal, for SA to implement a four-dose HBV 
vaccination schedule with the addition of the birth-dose vaccine 
within 24 hours of delivery. This would increase costs slightly but be 
easy to implement; moreover, it would not disrupt the current HBV 
vaccination schedule.
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Fibrinolytic therapy for acute 
myocardial infarction
Fibrinolytic therapy for acute myocardial infarction (AMI) became 
standard of care fully three decades ago, the best approach being to 
administer thrombolytic therapy as soon as possible to all patients 
without contraindications who present within 12 hours of symptom 
onset and have ST-segment elevation on the ECG or new-onset left 
bundle-branch block, unless an alternative reperfusion strategy is 
planned. Looking at reasons for delays in administering fibrinolytics 
to patients with AMI at Steve Biko Academic Hospital, Meel and 
Gonçalves[9] convey the dismaying news that the majority of patients 
(67%) presenting to the capital’s academic hospital did not receive 
fibrinolytic therapy at all. Even those who did received it after the 
‘golden’ 60 - 90 minutes when lysis of infarct artery thrombi may 
achieve reperfusion, thereby reducing infarct size, preserving left 
ventricular function and improving survival. 
A large number of eligible patients arrived at a facility in Pretoria 
capable of providing fibrinolytic therapy but did not receive any 
treatment! These missed opportunities will clearly result in excess 
mortality and morbidity, including heart failure, which would 
otherwise be preventable.
Migrant health
Climate change, as addressed in last month’s editorial and review,[10,11] 
is likely to result in the migration of human populations, especially 
in Africa, affecting disease transmission patterns, burdening 
healthcare systems and pressurising demand for healthcare services. 
An editorial[12] and a research article[13] touch on issues of migrant 
health. As the authors of the former point out, ‘Migration provides 
opportunities for health and economic benefits, and has the potential 
to positively and negatively affect health systems. To maximise 
positive impact, and mitigate against potential negative consequences, 
requires attention and engagement of policy-makers from health and 
other sectors, including public health researchers and health workers.’ 
It is postulated that a healthy migrant effect exists – studies con-
ducted in several parts of the world point to a pattern of better health 
in migrant groups compared with their compatriots who decide 
not to emigrate. Looking at the socioeconomic and environmental 
heath situation of international migrants in Johannesburg, Mathee 
and Naicker[13] show unexpectedly that, after controlling for 
socioeconomic status and area of residence, the health of migrants 
into SA was quite as bad as that of native citizens in respect of chronic 
diseases, mental ill health, and communicable and acute ill health, 
with a similar exposure to violence … probably because intra-African 
migration may not self-select high levels of health to the same degree 
as in people migrating from Africa to high-income countries. 
Climate change
Returning to the issue of climate change, the COP21 conference 
is in session as I write, with the aim of achieving an international 
consensus on how the world will keep global warming below 2oC. 
I suggested last month that we should not hold our respective breaths 
regarding consensus, or the pledge by developed countries to provide 
USD100 billion annually to developing nations to enable them to seek 
renewable energy sources. 
In this context, India’s prime minister Narendra Modi, speaking 
at COP21, has said that the choices for developing countries are 
not easy: ‘The prosperous still have a strong carbon footprint and 
the world’s billions in countries at the bottom of the development 
ladder are seeking space to grow.’ (Of India’s 1.25 billion people, 300 
million do not yet have access to energy.) Our own President Zuma 
drew a distinction between the roles of developed and developing 
countries‚ emphasising that the latter were already feeling the effects 
of global warming‚ much of the responsibility for which lay with 
the developed world.[14] In the midst of the worst drought in SA in 
decades, half a million people in KwaZulu-Natal are already facing 
hunger.[15]
Perhaps, predictably, the pledges made so far will result in global 
warming of at least 2.7oC, short of the 2oC goal. Moreover, negotiators 
seem to have given up on the idea that any pledges should be legally 
binding and there will be no real sanction, other than opprobrium, 
for those countries that renege on their undertakings in Paris.
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